{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T05:59:15Z","timestamp":1674712755466},"reference-count":27,"publisher":"American Society of Consultant Pharmacists","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:p>Pharmacy-based Opioid Use Disorder (OUD) treatment has been identified as a central pillar in curbing the spiraling opioid epidemic that claimed more than 100,000 lives in the United States in a one year period for the first time. This epidemic is also partially responsible for the plummeting US life expectancy that began prior to the COVID-19 pandemic and has now claimed more than 500,000 lives since 1999 with more than 70% of the 70,630 overdose deaths in 2019 involved with an opioid. Older people are at increased risk of both OUD and OUD-related complications. Recent studies have demonstrated that people older than 65 years of age were more likely to die of OUD-related complications, and - because of an increased likelihood of polypharmacy - are more likely to experience a drug interaction that magnifies the risk of an opioid-related misadventure.<\/jats:p>","DOI":"10.4140\/tcp.n.2023.47","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T20:56:31Z","timestamp":1674507391000},"page":"47-49","source":"Crossref","is-referenced-by-count":0,"title":["The Critical Role of Pharmacists in Treating Older People in the Opioid Crisis"],"prefix":"10.4140","volume":"38","author":[{"given":"Jonathan H.","family":"Watanabe","sequence":"first","affiliation":[{"name":"Professor of Clinical Pharmacy Associate Dean of Pharmacy Assessment and Quality Member Forum on Drug Discovery, Development, and Translation of the National Academies of Sciences, Engineering, and Medicine University of California,\n Irvine School of Pharmacy & Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","article-title":"US Overdose Deaths In 2021 Increased Half as Much as in 2020 - But Are Still Up 15%."},{"key":"ref2","year":"2021","journal-title":"Mortality in the United States, 2020."},{"key":"ref3","article-title":"Understanding the Epidemic: Drug Overdose.","year":"2022","journal-title":"CDC Injury Center."},{"key":"ref4","year":"2017"},{"key":"ref5","article-title":"Risk Factors for Opioid Misuse, Addiction, and Overdose.","year":"2022"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2020.17477","article-title":"Nonfatal opioid overdoses at an urban emergency department during the Covid-19 pandemic.","volume":"324","year":"2020","journal-title":"JAMA."},{"issue":"16","key":"ref7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.2020.18543","article-title":"The opioid epidemic during the covid-19 pandemic.","volume":"324","year":"2020","journal-title":"JAMA."},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1001\/jama.2020.17694","article-title":"Analysis of drug test results before and after the us declaration of a national emergency concerning the Covid-19 outbreak.","volume":"324","year":"2020","journal-title":"JAMA."},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","article-title":"Opioid use disorder and the Covid-19 pandemic: a call to sustain regulatory easements and further expand access to treatment.","volume":"41","year":"2020","journal-title":"Subst Abuse."},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","article-title":"Covid-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January-July 2020.","volume":"111","year":"2021","journal-title":"Am J Public Health."},{"key":"ref11","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the Covid-19 pandemic.","year":"2022","journal-title":"JAMA Psychiatry."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"106845","DOI":"10.1016\/j.ypmed.2021.106845","article-title":"Growing racial\/ ethnic disparities in overdose mortality before and during the Covid-19 pandemic in California.","volume":"153","year":"2021","journal-title":"Prev Med."},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/jamapsychiatry.2021.0967","article-title":"Racial\/ethnic, social, and geographic trends in overdose-associated cardiac arrests observed by US emergency medical services during the Covid-19 pandemic.","volume":"78","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"106532","DOI":"10.1016\/j.addbeh.2020.106532","article-title":"Drinking to cope with the pandemic: the unique associations of Covid-19-related perceived threat and psychological distress to drinking behaviors in American men and women.","volume":"110","year":"2020","journal-title":"Addict Behav."},{"issue":"12","key":"ref15","first-page":"17111724","article-title":"Alcohol and cigarette use and misuse among Hurricane Katrina survivors: psychosocial risk and protective factors.","volume":"44","year":"2009","journal-title":"Subst Use Misuse."},{"key":"ref16","article-title":"People With SUDs Have Increased Risk for COVID-19 and Worse Outcomes.","year":"2021","journal-title":"National Institute on Drug Abuse."},{"key":"ref17","article-title":"Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid Covid-19.","volume":"122","year":"2021","journal-title":"J Subst Abuse Treat."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"108387","DOI":"10.1016\/j.jsat.2021.108387","article-title":"Differential impacts of Covid-19 across racial-ethnic identities in persons with opioid use disorder.","volume":"129","year":"2021","journal-title":"J Subst Abuse Treat."},{"issue":"9810","key":"ref19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(11)61138-0","article-title":"Extent of illicit drug use and dependence, and their contribution to the global burden of disease.","volume":"379","year":"2012","journal-title":"Lancet."},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ADM.0000000000000260","article-title":"Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated healthcare system.","volume":"11","year":"2017","journal-title":"J Addict Med."},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/add.14607","article-title":"Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings.","volume":"114","year":"2019","journal-title":"Addiction."},{"key":"ref22","volume-title":"Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop.","year":"2022"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician\u2013 pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.","volume":"116","year":"2021","journal-title":"Addiction."},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/10826080802483936","article-title":"Supervised Methadone Consumption: Client Issues and Stigma.","volume":"44","year":"2009","journal-title":"Subst Use Misuse."},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jrh.12264","article-title":"Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in southwestern Ontario.","volume":"34","year":"2018","journal-title":"J Rural Health."},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment.","volume":"105","year":"2015","journal-title":"Am J Public Health."},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"e222839","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"to Buprenorphine Access at Retail Pharmacies in the US.","volume":"3","year":"2022","journal-title":"JAMA Health Forum."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2023\/00000038\/00000002\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T23:17:51Z","timestamp":1674688671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2023.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["2639-9636(20230201)38:2L.47;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2023.47","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}